Intuitive Surgical — Key Risks
China-Specific Headwinds Are Compounding Quickly
China represents a meaningful and growing part of Intuitive's business, but multiple pressures are converging there at once. An ongoing government anti-corruption campaign launched in July 2023 has delayed or canceled hospital purchasing tenders, provincial governments have capped what hospitals can charge patients for robotic surgeries, and domestic Chinese competitors are gaining ground. The 2023 national quota only permitted 559 new surgical robots to be sold across all vendors, and Intuitive had placed just 162 of its allocated da Vinci systems under that quota as of December 31, 2025 — far fewer than anticipated.
Tariffs Threaten Margins on the Company's Highest-Volume Products
Intuitive manufactures a significant majority of its instruments and accessories — the disposable parts that generate recurring revenue every time a surgery is performed — in Mexicali, Mexico. New U.S. tariffs imposed on Mexican imports in 2025 directly raise the cost of those products, squeezing the profit margin Intuitive earns and potentially making its systems less price-competitive compared to domestic alternatives abroad.
China's Rare Earth Export Controls Could Disrupt the Supply Chain
In 2025, the Chinese government announced export controls and licensing requirements on products containing Chinese-origin rare earth elements, which are critical components in Intuitive's devices. China is the world's predominant producer of these materials. If these controls tighten further, Intuitive could face parts shortages, production delays, and an inability to fulfill customer orders — with little ability to quickly switch to alternative suppliers.
Usage-Based Leasing Creates Revenue Volatility and Credit Risk
Intuitive is increasingly placing systems under arrangements where hospitals pay based on how many procedures they perform, rather than buying the system outright. If a hospital performs fewer surgeries than expected — due to budget cuts, staffing shortages, or economic pressure — Intuitive collects less revenue. Certain lease agreements also allow customers to cancel or return systems without a financial penalty, meaning Intuitive could be left with depreciated assets it cannot fully recover.
Reimbursement Pressure Could Limit Procedure Growth
Intuitive's revenue depends heavily on hospitals being adequately reimbursed by insurers and government programs for robotic-assisted procedures. In China, multiple provinces have already imposed hard caps on what hospitals can charge for robotic surgery, visibly reducing both the number of procedures performed and the prices Intuitive can charge for its instruments. Similar pressure from U.S. healthcare reform or budget-driven changes to Medicare and Medicaid reimbursement could dampen procedure volumes domestically.
GLP-1 Weight-Loss Drugs Are Already Reducing One Procedure Category
The filing explicitly acknowledges that popular GLP-1 drugs (like Ozempic and Wegovy), originally approved for diabetes and then for weight loss, have already reduced the number of bariatric (weight-loss) surgeries performed using da Vinci systems. If these drugs expand to treat other conditions that Intuitive's systems currently address — such as certain cardiac or metabolic conditions — the long-term impact on procedure volumes could be significantly larger than what has been seen so far.
Unauthorized Remanufactured Instruments Threaten a Core Revenue Stream
A significant portion of Intuitive's revenue comes from selling single-use or limited-use instruments and accessories. Third parties have already received FDA clearance to remanufacture certain of these instruments for re-use with Intuitive's da Vinci Si, X, and Xi systems — meaning a hospital could legally buy a cheaper refurbished instrument instead of a new one from Intuitive. This directly erodes the recurring, high-margin revenue stream that makes the business model work.